ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 186 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $215,249 | -6.2% | 23,145 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $229,367 | +206.8% | 23,145 | 0.0% | 0.00% | +100.0% |
| Q4 2023 | $74,758 | -39.2% | 23,145 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $122,900 | -66.2% | 23,145 | -39.3% | 0.00% | -75.0% |
| Q2 2023 | $363,522 | +42.8% | 38,145 | +64.8% | 0.00% | 0.0% |
| Q1 2023 | $254,595 | -25.7% | 23,145 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $342,546 | -22.5% | 23,145 | 0.0% | 0.01% | -25.0% |
| Q3 2022 | $442,000 | -10.3% | 23,145 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $493,000 | +10.5% | 23,145 | 0.0% | 0.01% | +60.0% |
| Q1 2022 | $446,000 | -7.1% | 23,145 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $480,000 | -13.2% | 23,145 | 0.0% | 0.01% | -16.7% |
| Q3 2021 | $553,000 | – | 23,145 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |